Biotech · Public company · Wayne, PA, US

Avalo Therapeutics, Inc.

Ticker AVTX · SEC CIK 0001534120

Track this companyFree. Adds Avalo Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials50 recruiting or active

Pipeline programs6From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline6

AVTX-002Phase 2 · Non-Eosinophilic AsthmaClinicalTrials.gov · fetched Nov 12, 2026
AVTX-009 Regimen 1Phase 2 · Hidradenitis SuppurativaClinicalTrials.gov · fetched Nov 12, 2026
AVTX-009 Regimen 2Phase 2 · Hidradenitis SuppurativaClinicalTrials.gov · fetched Nov 12, 2026
AEVI-007Phase 1 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
CERC-006Phase 1 · Lymphatic MalformationClinicalTrials.gov · fetched Nov 12, 2026
MDGN-002Phase 1 · Crohn DiseaseClinicalTrials.gov · fetched Nov 12, 2026

A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis SuppurativaPHASE2 · COMPLETED · started Sep 16, 2024ClinicalTrials.gov NCT06603077 · fetched Nov 12, 2026
A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.PHASE2 · COMPLETED · started Feb 24, 2022ClinicalTrials.gov NCT05288504 · fetched Nov 12, 2026
A Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of CERC-006 in Adults With Complex Lymphatic MalformationsPHASE1 · WITHDRAWN · started Sep 3, 2021ClinicalTrials.gov NCT04994002 · fetched Nov 12, 2026
Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple MyelomaPHASE1 · COMPLETED · started Dec 15, 2020ClinicalTrials.gov NCT04671251 · fetched Nov 12, 2026
Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative ColitisPHASE1 · TERMINATED · started Jul 14, 2017ClinicalTrials.gov NCT03169894 · fetched Nov 12, 2026